International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 2, Issue 15 | Case Report | Open Access
Saba Suleman*
Baylor Scott & White All Saints, USA
*Correspondence to: Saba Suleman
Fulltext PDFPemphigus foliaceus, a rare autoimmune condition, is one among several entities that make up a group of life threatening blistering disorders called pemphigus. It is distinguished by isolated cutaneous involvement and subcorneal acantholytic blisters. Considering the risks associated with a delayed diagnosis or misdiagnosis and the potential for overlap in clinical features and treatment, evaluation for suspected pemphigus disease often requires thorough clinical assessment an laboratory testing. Diagnosis is focused on individual biopsies for histopathology and direct immunofluorescence.
Drugs are the most common trigger of pemphigus. Tirzepatide is a relatively new drug that is FDA approved for glycemic control in adults with Type II Diabetes Mellitus. Here, we present a 63 year old female who presented with arthralgias and diffuse, blistering ulceration 1-2 days after initiating tirzepatide for her Type II diabetes. These lesions spread down both of her arms, legs, and feet with satellite lesions below her breasts. Upon another dose of tirzepatide, she noticed worsening of her symptoms and experienced mild fever, chills, and appetite changes. She
presented to the hospital with cellulitis of her wounds and was treated with three weeks of vancomycin and cefepime. Biopsy results and clinical presentation led to a diagnosis of pemphigus foliaceus. Tirzepatide was stopped and she was treated with a prednisone taper course. She had significant improvement of her lesions upon initiation of antibiotics and steroids and was stable for discharge.
Pemphigus foliaceus; Pemphigus; Drugs
Saba Suleman, Ramlah Khan, Cerin Tomson, Ahmed Abdelmonem. Pemphigus Foliaceus following Tirzepatide Use. Int Clinc Med Case Rep Jour. 2023;2(15):1-5.